1.895
price down icon16.59%   -0.365
 
loading
Precedente Chiudi:
$2.26
Aprire:
$2.28
Volume 24 ore:
4.09M
Relative Volume:
3.91
Capitalizzazione di mercato:
$101.42M
Reddito:
-
Utile/perdita netta:
$-67.68M
Rapporto P/E:
-1.0954
EPS:
-1.73
Flusso di cassa netto:
$-54.24M
1 W Prestazione:
-50.13%
1M Prestazione:
-58.30%
6M Prestazione:
-84.54%
1 anno Prestazione:
-89.30%
Intervallo 1D:
Value
$1.85
$2.30
Intervallo di 1 settimana:
Value
$1.85
$3.84
Portata 52W:
Value
$1.85
$26.35

Cabaletta Bio Inc Stock (CABA) Company Profile

Name
Nome
Cabaletta Bio Inc
Name
Telefono
(267) 759-3100
Name
Indirizzo
2929 ARCH STREET, PHILADELPHIA, PA
Name
Dipendente
154
Name
Cinguettio
@CabalettaBio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
CABA's Discussions on Twitter

Confronta CABA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
CABA 1.899 101.42M 0 -67.68M -54.24M -1.73
VRTX 450.39 115.43B 10.63B -479.80M -1.35B 13.33
REGN 749.43 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 589.59 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.81 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.90 24.89B 3.30B -501.07M 1.03B 11.54

Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-09-05 Iniziato Citigroup Buy
2023-07-18 Iniziato Guggenheim Buy
2023-01-27 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-08-30 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-12-08 Iniziato Wells Fargo Overweight
2021-10-19 Ripresa Morgan Stanley Overweight
2021-06-30 Iniziato Mizuho Buy
2021-01-08 Iniziato Chardan Capital Markets Buy
2020-10-13 Iniziato H.C. Wainwright Buy
2019-11-19 Iniziato Cowen Outperform
2019-11-19 Iniziato Evercore ISI Outperform
2019-11-19 Iniziato Morgan Stanley Overweight
Mostra tutto

Cabaletta Bio Inc Borsa (CABA) Ultime notizie

pulisher
03:00 AM

Cabaletta Bio Unveils Promising Data on CABA-201 at ACR Convergence 2024 - MyChesCo

03:00 AM
pulisher
Nov 20, 2024

Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim’s Healthcare Innovation Conference! - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Cabaletta Bio shares retain Buy rating as H.C. Wainwright sees robust treatment effect - Investing.com

Nov 19, 2024
pulisher
Nov 18, 2024

Cabaletta Bio Reports Q3 2024 Financial Results - TipRanks

Nov 18, 2024
pulisher
Nov 18, 2024

Cabaletta reports promising autoimmune therapy results By Investing.com - Investing.com Canada

Nov 18, 2024
pulisher
Nov 18, 2024

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 - The Manila Times

Nov 18, 2024
pulisher
Nov 18, 2024

Cabaletta reports promising autoimmune therapy results - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Cabaletta Bio’s (CABA) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 18, 2024
pulisher
Nov 15, 2024

Cabaletta Bio (NASDAQ:CABA) Given New $12.00 Price Target at Wells Fargo & Company - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Cabaletta Bio stock hits 52-week low at $3.47 amid market challenges - Investing.com UK

Nov 15, 2024
pulisher
Nov 15, 2024

Cabaletta Bio (NASDAQ:CABA) Earns "Buy" Rating from HC Wainwright - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Cabaletta Bio Inc. (CABA) Quarterly 10-Q Report - Quartz

Nov 15, 2024
pulisher
Nov 14, 2024

T. Rowe Price Investment Management, Inc. Reduces Stake in Cabal - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Guggenheim maintains Buy on Cabaletta Bio with $23 target - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

Guggenheim maintains Buy on Cabaletta Bio with $23 target By Investing.com - Investing.com UK

Nov 14, 2024
pulisher
Nov 14, 2024

Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 14, 2024
pulisher
Nov 08, 2024

Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim's Healthcare Innovation Conference! - MyChesCo

Nov 08, 2024
pulisher
Nov 06, 2024

Cabaletta Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference - Yahoo Finance

Nov 06, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition of Cabaletta Bio Inc Shares - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Nov 04, 2024
pulisher
Nov 03, 2024

UBS Initiates Coverage of Cabaletta Bio (CABA) with Buy Recommendation - MSN

Nov 03, 2024
pulisher
Oct 30, 2024

We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate - Yahoo Finance

Oct 30, 2024
pulisher
Oct 28, 2024

Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Down 28.9% in October - MarketBeat

Oct 28, 2024
pulisher
Oct 25, 2024

Undercovered Dozen: CorMedix, Cabaletta, Skyx Platforms, Dynex Capital + - Seeking Alpha

Oct 25, 2024
pulisher
Oct 22, 2024

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash - Seeking Alpha

Oct 22, 2024
pulisher
Oct 17, 2024

State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings - Yahoo Finance

Oct 17, 2024
pulisher
Oct 17, 2024

State Street Corp's Strategic Reduction in Cabaletta Bio Inc Hol - GuruFocus.com

Oct 17, 2024
pulisher
Oct 14, 2024

Short Interest in Cabaletta Bio, Inc. (NASDAQ:CABA) Drops By 16.7% - MarketBeat

Oct 14, 2024
pulisher
Oct 14, 2024

Trading Day Review: Cabaletta Bio Inc (CABA) Gains Momentum, Closing at 4.21 - The Dwinnex

Oct 14, 2024
pulisher
Oct 12, 2024

Millennium Management LLC Grows Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Oct 12, 2024
pulisher
Oct 11, 2024

Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential - MSN

Oct 11, 2024
pulisher
Oct 11, 2024

UBS sees significant upside for Cabaletta Bio despite recent share decline - Investing.com India

Oct 11, 2024
pulisher
Oct 10, 2024

Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential (NASDAQ:KYTX) - Seeking Alpha

Oct 10, 2024
pulisher
Oct 10, 2024

Healthy Upside Potential: Cabaletta Bio Inc (CABA) - SETE News

Oct 10, 2024
pulisher
Oct 10, 2024

UBS sees significant upside for Cabaletta Bio despite recent share decline By Investing.com - Investing.com South Africa

Oct 10, 2024
pulisher
Oct 10, 2024

Cabaletta Bio (NASDAQ:CABA) Now Covered by Analysts at UBS Group - MarketBeat

Oct 10, 2024
pulisher
Oct 10, 2024

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

A Guide To The Risks Of Investing In Cabaletta Bio Inc (CABA) - Knox Daily

Oct 09, 2024
pulisher
Oct 07, 2024

Cabaletta Bio Inc (CABA) stock analysis: A comprehensive overview - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

Cabaletta Bio Outlines Future Trials and Development Strategy - TipRanks

Oct 07, 2024
pulisher
Oct 04, 2024

Squarepoint Ops LLC Has $2.36 Million Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Oct 04, 2024
pulisher
Oct 04, 2024

Marshall Wace LLP Grows Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Oct 04, 2024
pulisher
Oct 02, 2024

Get in on Cabaletta Bio Inc’s (CABA) buy-in window today! - SETE News

Oct 02, 2024
pulisher
Oct 01, 2024

Should investors be concerned about Cabaletta Bio Inc (CABA)? - US Post News

Oct 01, 2024
pulisher
Oct 01, 2024

Cabaletta Bio Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle

Oct 01, 2024
pulisher
Oct 01, 2024

Cabaletta Bio secures lease terms through August 2026 - Investing.com India

Oct 01, 2024
pulisher
Sep 30, 2024

Cabaletta Bio secures lease terms through August 2026 By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 30, 2024

Ratios Reveal: Breaking Down Cabaletta Bio Inc (CABA)’s Financial Health - The Dwinnex

Sep 30, 2024
pulisher
Sep 30, 2024

Perceptive Advisors LLC Cuts Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Sep 30, 2024

Cabaletta Bio Inc Azioni (CABA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Cabaletta Bio Inc Azioni (CABA) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Binder Gwendolyn
See Remarks
Jan 19 '24
Sale
19.59
11,000
215,439
20,000
Binder Gwendolyn
See Remarks
Dec 19 '23
Option Exercise
1.01
11,000
11,110
31,000
Binder Gwendolyn
See Remarks
Dec 19 '23
Sale
21.89
11,000
240,789
20,000
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):